LifeGel
Pre-clinical- Indications
- Spinal surgery bleeding
Company intelligence / Profile preview
Medcura has developed a proprietary platform of hemostatic agents—gels, foams, powders—designed to rapidly stop bleeding in surgical and trauma settings. Lead product LifeGel™ received FDA Breakthrough Device Designation for use in spinal surgery due to its non-swelling property. LifeFoam™ also received Breakthrough Device Designation for traumatic wounds. The company has five FDA clearances and two Breakthrough Device Designations[2][4]. Clinical results are promising but pivotal trials are ongoing.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medcura.